831 related articles for article (PubMed ID: 9550501)
1. Therapeutic efficacy of the lipid-lowering armamentarium: the clinical benefits of aggressive lipid-lowering therapy.
Hunninghake DB
Am J Med; 1998 Feb; 104(2A):9S-13S. PubMed ID: 9550501
[TBL] [Abstract][Full Text] [Related]
2. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts.
Post Coronary Artery Bypass Graft Trial Investigators
N Engl J Med; 1997 Jan; 336(3):153-62. PubMed ID: 8992351
[TBL] [Abstract][Full Text] [Related]
3. The effect of aggressive and moderate lowering of LDL-cholesterol and low dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial.
Alaupovic P; Fesmire JD; Hunnighake D; Domanski M; Forman S; Knatterud GL; Forrester J; Herd JA; Hoogwerf B; Campeau L; Gobel FL
Atherosclerosis; 1999 Oct; 146(2):369-79. PubMed ID: 10532693
[TBL] [Abstract][Full Text] [Related]
4. Benefit of aggressive lipid-lowering therapy: insights from the post coronary artery bypass graft study and other trials.
White CW
Am J Med; 1998 Jul; 105(1A):63S-68S. PubMed ID: 9707270
[TBL] [Abstract][Full Text] [Related]
5. Pleiotropic effect of lovastatin, with and without cholestyramine, in the post coronary artery bypass graft (Post CABG) trial.
Domanski M; Tian X; Fleg J; Coady S; Gosen C; Kirby R; Sachdev V; Knatterud G; Braunwald E
Am J Cardiol; 2008 Oct; 102(8):1023-7. PubMed ID: 18929703
[TBL] [Abstract][Full Text] [Related]
6. Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol.
Stewart BF; Brown BG; Zhao XQ; Hillger LA; Sniderman AD; Dowdy A; Fisher LD; Albers JJ
J Am Coll Cardiol; 1994 Mar; 23(4):899-906. PubMed ID: 8106695
[TBL] [Abstract][Full Text] [Related]
7. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
Evans M; Roberts A; Davies S; Rees A
Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
[TBL] [Abstract][Full Text] [Related]
8. Cholesterol lowering in the management of coronary artery disease: the clinical implications of recent trials.
Eisenberg DA
Am J Med; 1998 Feb; 104(2A):2S-5S. PubMed ID: 9550499
[TBL] [Abstract][Full Text] [Related]
9. Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial. Post CABG Trial Investigators.
Campeau L; Hunninghake DB; Knatterud GL; White CW; Domanski M; Forman SA; Forrester JS; Geller NL; Gobel FL; Herd JA; Hoogwerf BJ; Rosenberg Y
Circulation; 1999 Jun; 99(25):3241-7. PubMed ID: 10385497
[TBL] [Abstract][Full Text] [Related]
10. [Lipid intervention and coronary heart disease in men less than 56 years of age. The Coronary Intervention Study: CIS].
Rensing UF; Bestehorn HP; Roskamm H; Petersen J; Betz P; Spinder M; Benesch L; Schemeitat K; Blümchen G; Claus J; Wieland H; Böcker JF; Neiss A; Stiepel E; Mathes P; Kappenberger L; Braunagel K; Peters K; Meister G; Samek L; Schuon J; Leimenstoll B; Kiefer H
Z Kardiol; 1999 Apr; 88(4):270-82. PubMed ID: 10408031
[TBL] [Abstract][Full Text] [Related]
11. [Statins in primary prevention of coronary heart disease].
Paulweber B
Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
[TBL] [Abstract][Full Text] [Related]
12. Profiling risk and new therapeutic interventions: looking ahead.
Shepherd J
Am J Med; 1998 Feb; 104(2A):19S-22S. PubMed ID: 9550503
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Plans-Rubió P
Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
[TBL] [Abstract][Full Text] [Related]
14. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
Shepherd J; Hunninghake DB; Barter P; McKenney JM; Hutchinson HG
Am J Cardiol; 2003 Mar; 91(5A):11C-17C; discussion 17C-19C. PubMed ID: 12646338
[TBL] [Abstract][Full Text] [Related]
15. Achieving LDL-C target levels: the role of statins.
Lablanche JM
Curr Med Res Opin; 2001; 16(4):285-95. PubMed ID: 11268713
[TBL] [Abstract][Full Text] [Related]
16. Managing dyslipidemia in the high-risk patient.
Stein EA
Am J Cardiol; 2002 Mar; 89(5A):50C-57C. PubMed ID: 11900720
[TBL] [Abstract][Full Text] [Related]
17. The effect of simvastatin on progression of coronary artery disease. The Multicenter coronary Intervention Study (CIS).
Bestehorn HP; Rensing UF; Roskamm H; Betz P; Benesch L; Schemeitat K; Blümchen G; Claus J; Mathes P; Kappenberger L; Wieland H; Neiss A
Eur Heart J; 1997 Feb; 18(2):226-34. PubMed ID: 9043838
[TBL] [Abstract][Full Text] [Related]
18. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.
Nissen SE; Tuzcu EM; Schoenhagen P; Brown BG; Ganz P; Vogel RA; Crowe T; Howard G; Cooper CJ; Brodie B; Grines CL; DeMaria AN;
JAMA; 2004 Mar; 291(9):1071-80. PubMed ID: 14996776
[TBL] [Abstract][Full Text] [Related]
19. The impact of lipid lowering in coronary artery disease.
Goldberg AC
Curr Opin Cardiol; 1997 Sep; 12(5):488-93. PubMed ID: 9352177
[TBL] [Abstract][Full Text] [Related]
20. Effect of an aggressive lipid-lowering strategy on progression of atherosclerosis in the left main coronary artery from patients in the post coronary artery bypass graft trial.
White CW; Gobel FL; Campeau L; Knatterud GL; Forman SA; Forrester JS; Geller NL; Herd JA; Hickey A; Hoogwerf BJ; Hunninghake DB; Rosenberg Y; Terrin ML;
Circulation; 2001 Nov; 104(22):2660-5. PubMed ID: 11723015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
